Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 AMG 211 continuous intravenous infusion in relapsed or refractory gastrointestinal adenocarcinoma
NL-OMON44202Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2014
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AMG 211 in gastrointestinal adenocarcinoma (GIAC), sponsored by Amgen. Primary endpoints: Safety and tolerability of AMG 211 and Maximum tolerated dose and/or biologically active dose. Started Dec 2014; status: active, not recruiting.
02
Drugs
AMG 211
03
Conditions
gastrointestinal adenocarcinoma (GIAC)
Beyond the preview
Go deeper on NL-OMON44202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44202.